Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Barinthus Biotherapeutics (BRNS)

Annual Return

Over the past 3 years, BRNS has had an average annual return of -35.27%, underperforming the benchmark SPY, which returned +19.62% annual.

Over the past 5 years, BRNS has had an average annual return of -47.21%, underperforming the benchmark SPY, which returned +12.73% annual.

Since Apr 30, 2021, BRNS has had an average annual return of -45.22%, underperforming the benchmark SPY, which returned +13.35% annual.

202620252024202320222021
-13.48%-42.01%-67.25%+56.99%-78.84%-21.21%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026+4.23%-20.08%-2.42%+14.11%+4.77%-3.11%-8.12%-13.48%
2025-9.33%-7.85%-3.63%+15.07%-3.53%-13.84%+59.09%-24.38%+11.71%+5.30%-40.04%-11.25%-42.01%
2024-25.49%+2.92%-15.89%-13.86%-6.81%-26.72%+6.45%-11.73%-9.54%+25.24%-33.87%+22.60%-67.25%
2023+20.40%-1.40%-19.71%+3.08%+6.29%-16.08%+11.64%-15.21%+58.42%+35.97%-32.02%+29.23%+56.99%
2022-17.10%-24.11%-25.60%+3.42%-20.03%+3.48%+9%-10.32%-26.42%-13.44%-19.13%+4.91%-78.84%
2021+0%+4.82%+13.54%-13.23%+3.91%+4.04%-12.33%-11.44%-9.09%-21.21%

Drawdown analysis of Barinthus Biotherapeutics (BRNS)

The maximum drawdown for the BRNS was -96.82%, occurring on Apr 1, 2026. This drawdown has not yet recovered.

The current BRNS drawdown is -96.43%.

Since Apr 30, 2021 BRNS has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 1 time
  • 10% or more: 1 time
DepthStartTo BottomBottomTo RecoverEndTotal
-96.82%May 17, 20211224Apr 1, 2026OngoingOngoingOngoing
-8.56%May 3, 20212May 5, 20215May 12, 20217